Patents by Inventor Algis Anilionis

Algis Anilionis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5961983
    Abstract: This invention pertains to a complementation system for the selection and maintenance of expressed genes in bacterial hosts. The invention provides stable vectors which can be selected and maintained by complementation of chromosomal deletion mutations of purA (adenylosuccinate synthetase), obviating the use of antibiotic resistance genes. This system is useful in production organisms during fermentation and in live vaccine bacteria, such as attenuated Salmonella typhi. This system allows for selection of chromosomal integrants and for selection and stable plasmid maintenance in the vaccinated host without application of external selection pressure.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: October 5, 1999
    Assignee: Praxis Biologics, Inc.
    Inventors: Robert N. Brey, James P. Fulginiti, Algis Anilionis
  • Patent number: 5919663
    Abstract: This invention pertains to a complementation system for the selection and maintenance of expressed genes in bacterial hosts. The invention provides stable vectors which can be selected and maintained by complementation of chromosomal deletion mutations of purA (adenylosuccinate synthetase), obviating the use of antibiotic resistance genes. This system is useful in production organisms during fermentation and in live vaccine bacteria, such as attenuated Salmonella typhi. This system allows for selection of chromosomal integrants and for selection and stable plasmid maintenance in the vaccinated host without application of external selection pressure.
    Type: Grant
    Filed: January 30, 1995
    Date of Patent: July 6, 1999
    Assignee: American Cyanamid Company
    Inventors: Robert N. Brey, James P. Fulginiti, Algis Anilionis
  • Patent number: 5616473
    Abstract: The gene encoding the ligninase rLDM.TM. 6 has been cloned and expressed. The ligninases produced via the processes disclosed herein are useful to degrade or modify lignin in pulp operations.
    Type: Grant
    Filed: August 8, 1994
    Date of Patent: April 1, 1997
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Roberta L. Farrell, Paul Gelep, Algis Anilionis, Kashayar Javaherian, Theodore E. Maione, James Rusche, Bruce A. Sadownick, Jennifer A. Jackson
  • Patent number: 5196338
    Abstract: Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 and PBOMP-2 related peptides, proteins and fusion proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides, proteins, and fusion proteins in appropriate host cells. The peptides, proteins, fusion proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections.
    Type: Grant
    Filed: February 15, 1990
    Date of Patent: March 23, 1993
    Assignee: Praxis Biologics, Inc.
    Inventors: Algis Anilionis, Robert C. Seid, Jr., Robert A. Deich, Gary W. Zlotnick, Bruce A. Green
  • Patent number: 5151350
    Abstract: The gene coding for a protein A-like material has been successfully cloned and expressed for the first time. The cloning of this gene with its nucleotide sequence characterization, also disclosed, enables those skilled in the art to obtain quantities of a protein A-like material nucleotide sequence for cloning in various host-vector systems. Protein A is well known as a valuable component of a variety of diagnostic test systems. The protein A-like material of the subject invention, and subfragments thereof, have the protein A properties of binding to IgG at the Fc region and activation of polyclonal antibody synthesis. Thus, these entities are useful in the same manner as protein A.
    Type: Grant
    Filed: October 27, 1982
    Date of Patent: September 29, 1992
    Assignee: Repligen Corporation
    Inventors: Donald A. Colbert, Algis Anilionis
  • Patent number: 5110905
    Abstract: The subject invention is directed to a novel Bacillus thuringiensis kurstaki .delta.-endotoxin prepared by use of a novel hybrid gene. This gene is cloned into a novel plasmid which is transformed into a prokaryotic host. The .delta.-endotoxin of the subject invention is active against Lepidoptera larvae.
    Type: Grant
    Filed: July 27, 1990
    Date of Patent: May 5, 1992
    Assignee: Repligen Corporation
    Inventors: Daniel P. Witt, Donald A. Colbert, Algis Anilionis
  • Patent number: 5098997
    Abstract: Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 and PBOMP-2 related peptides, proteins and fusion proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides, proteins, and fusion proteins in appropriate host cells. The peptides, proteins, fusion proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections.
    Type: Grant
    Filed: September 1, 1988
    Date of Patent: March 24, 1992
    Assignee: Praxis Biologics, Inc.
    Inventors: Algis Anilionis, Robert C. Seid, Jr., Robert A. Deich, Gary W. Zlotnick, Bruce A. Green
  • Patent number: 4952682
    Abstract: A novel highly effective prokaryotic expression system is exemplified specifically by being used to produce the useful enzyme .beta.-glucuronidase (BG). This system uses a hybrid plasmid comprising BG gene promoter DNA. The level of expression of BG by an E. coli K-12 derivative host is in the 50% of total cellular protein range. The invention expression system also can be used to express other useful proteins, as disclosed herein.
    Type: Grant
    Filed: September 30, 1988
    Date of Patent: August 28, 1990
    Assignee: Repligen Corporation
    Inventors: Algis Anilionis, John L. Palmer
  • Patent number: 4888280
    Abstract: Hybrid useful proteins are prepared by a novel biological system comprising a prokaryotic host transformed with novel hybrid plasmids' .beta.-glucuronidase (BG) gene DNZ and the desired protein gene DNA. Specifically exemplified are plasmids which comprise BG gene DNA and protein A DNA. E. coli K-12 derivative hosts transformed with plasmid pBG3-2.DELTA.n express >60% of the desired fusion protein having protein A-like biological activity. Other useful proteins can be expressed via the elegant highly efficient expression system of the subject invention.
    Type: Grant
    Filed: August 25, 1986
    Date of Patent: December 19, 1989
    Assignee: Repligen Corporation
    Inventors: John L. Palmer, Algis Anilionis
  • Patent number: 4721671
    Abstract: A novel highly effective prokaryotic expression system is exemplified specifically by being used to produce the useful enzyme .beta.-glucuronidase (BG). This system uses a hybrid plasmid comprising BG gene promotor DNA. The level of expression of BG by an E. coli K-12 derivative host is in the 50% of total cellular protein range. The invention expression system also can be used to express other useful proteins, as disclosed herein.
    Type: Grant
    Filed: December 26, 1984
    Date of Patent: January 26, 1988
    Assignee: Repligen Corporation
    Inventors: Algis Anilionis, John L. Palmer
  • Patent number: 4691009
    Abstract: Hybrid useful proteins are prepared by a novel biological system comprising a prokaryotic host transformed with novel hybrid plasmids' .beta.-glucuronidase (BG) gene DNA and the desired protein gene DNA. Specifically exemplified are plasmids which comprise BG gene DNA and protein A DNA. E. coli K-12 derivative hosts transformed with plasmid pBG3-2.DELTA.N express >60% of the desired fusion protein having protein A-like biological activity. Other useful proteins can be expressed via the elegant highly efficient expression system of the subject invention.
    Type: Grant
    Filed: December 26, 1984
    Date of Patent: September 1, 1987
    Assignee: Repligen Corporation
    Inventors: John L. Palmer, Algis Anilionis